Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.
Notice bibliographique
Résumé
Abstract Background: Improved overall survival (OS) over time has been observed in large population databases assessing patients (pts) with MM. Recent interventions, such as routine use of bisphosphonates, and stem cell transplantation for younger pts may account for some of this improvement. It is unclear whether these improvements have been seen in older symptomatic pts. The purpose of this study is to assess outcomes over time of pts > 65 yrs with MM who were entered on 3 consecutive randomized trials conducted by NCIC CTG. Methods: Databases evaluated included MY4 (1983–84; N=173), which compared etidronate to placebo; MY6 (1987–92; N=402), which tested the role of maintenance interferon; and MY7 (1995–2003; N=584), which tested dexamethasone as induction and maintenance therapy. All pts had symptomatic Salmon-Durie stage I or stage II–III MM, were previously untreated, and received melphalan 9 mg/M2 and prednisone 100 mg daily x 4, Q4 weeks; 231 pts in MY7 received melphalan and dexamethasone according to random allocation. We performed uni- and multivariate analyses to compare outcomes of pts ≤ 65 and > 65 yrs of age, to assess outcomes of pts > 65 yrs over time, and to assess other prognostic determinants in pts > 65 yrs. Outcomes of interest included OS, progression-free survival (PFS), myeloma-related survival (MRS), defined as time from registration or randomization until death from myeloma or treatment toxicity, and time from first progression to death (FPTD). Results: All eligible pts were included. By multivariate analyses, patients > 65 yrs had inferior OS (p=0.0003), FPTD (p=0.0006), and a trend for inferior MRS (p=0.08) in comparison with pts ≤ 65 yrs; no difference in PFS was detected. In comparing pts >65 yrs on MY4, MY6 and MY7, important differences in the baseline characteristics of the patients of the 3 trials were noted; pts treated on MY6 received lower median cumulative doses of melphalan (356 mg/M2) than those entered on to MY4 (432 mg/M2) or MY-7 (464 mg/M2). Median unadjusted outcomes of these pts by trial are listed in the table below. By multivariate analysis, pts > 65 yrs entered on to MY4 had a superior MRS in comparison with MY7 (p=0.037) and a trend to superior OS (p=0.053) and FPTD (p=0.06). No differences in PFS between trials were detected. Baseline characteristics associated with inferior OS in pts > 65 yrs included ECOG PS > 1 (p=0.0002), male gender (p=0.001), baseline Hb ≤ 85 g/L (p=0.001), and elevated baseline serum calcium (p=0.01). Conclusions: Patients > 65 yrs have inferior outcomes in comparison with younger pts. We were unable to detect improvements in outcomes of these pts over time. Median unadjusted outcomes of pts age > 65 yrs by trial MY4 (95% CI) MY6 (95% CI) MY7 (95% CI) OS (yrs) 2.38 (1.73–3.32) 2.75 (2.36–3.24) 2.53 (2.32–2.75) PFS (yrs) 1.00 (0.90–1.41) 1.53 (1.38–1.75) 1.80 (1.61–1.92) MRS (yrs) 2.98 (1.78–3.59) 3.30 (2.66–3.79) 2.90 (2.61–3.22) FPTD (yrs) 1.21 (0.76–1.91) 1.27 (0.84–2.02) 0.85 (0.68–1.07)
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,010 | 0,012 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,003 |
| Bibliométrie | 0,001 | 0,003 |
| Études des sciences et des technologies | 0,001 | 0,001 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».